Human fibroblast diffusable factors

Details Human fibroblast diffusable factors Human fibroblast diffusable factors

1997-07-23

2000-11-21

Nashed, Nashaat T.

Drug, bio-affecting and body treating compositions

Extract, body fluid, or cellular material of undetermined...

4351731, A61K 3512, C12N 1300

Patent

active

061499455

ABSTRACT:
The present invention provides for numerous cell factors involved in a novel cellular pathway that is activated in response to ionizing radiation. Several cell factor activities are described which either complement the radioresistant DNA synthesis phenotype of Ataxia Telangiectasia cells, or inhibit DNA synthesis in the cell. Other cell factor activities are described which inhibit mitosis by arresting the cell cycle prior to cell division. It is contemplated that compositions comprising the subject factors will be useful as both research tools, and as therapeutic agents.

REFERENCES:
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5424400 (1995-06-01), Smith
Coffman et al. "Control of DNA replication in a transformed lymphoid cell line: Coexistence of activator and inhibitor activities" Cellu. Immunol. 138, 381-389, 1991.
El-Deiry et al. "WAF1, a potential mediator of p53 tumor suppression" Cell 75, 817-825, 1993.
Waga et al. "The p21 inhibitor of cyclin-dependent kinases control DNA replication by interaction with PCNA" Nature 369, 574-578, Jun. 1994.
Akagi et al., 1987, "Mitogenic and Antimitogenic Transforming Growth Factors Secreted by Adenovirus 2- and Simian Virus 40-transformed Hamster Cells: Possible Roles in Promoting Tumorigenesis," Cancer Res. 47:4086-4092.
Aurias and Dutrillaux, 1986, "A possible new type of chromosome rearrangement: telomere-centromere translocation (tct) followed by double duplication," Hum. Genet. 72:25-26.
Aurias and Dutrillaux, 1986, "Probable involvement of immunoglobulin superfamily genes in most recurrent chromosomal rearrangements from ataxia telangiectasia," Hum. Genet. 72:210-214.
Bar et al., 1978, "Extreme Insulin Resistance in Ataxia Telangiectasia: Defect in Affinity of Insulin Receptors," New Eng. J. Med. 298:1164-1171.
Bigbee et al., 1989, "Evidence for an Elevated Frequency of In Vivo Somatic Cell Mutations in Ataxia Telangiectasia," Am. J. Hum. Genet. 44:402-408.
Carter et al., 1992, "Humanization of an anti-p185.sup.HER2 antibody for human cancer therapy," Proc. Natl. Acad. Sci. U.S.A. 89:4285-4289.
Coffin, J., In: RNA Tumor Viruses, Weiss, R. et al. (eds.), Cold Spring Harbor Laboratory, vol. 2, pp. 36-38 (1985).
Cole et al., 1985, "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer," Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96.
Croce et al., 1985, "Gene for .alpha.-Chain of Human T-Cell Receptor: Location on Chromosome 14 Region Involved in T-Cell Neoplasms," Science 227:1044-1047.
Gatti et al., 1991, "Ataxia-Telangiectasia: An Interdisciplinary Approach to Pathogenesis," Medicine 70:99-117.
Hartwell, 1992, "Defects in a Cell Cycle Checkpoint May Be Responsible for the Genomic Instability of Cancer Cells," Cell 71:543-546.
Hartwell and Weinert, 1989, "Checkpoints: Controls That Ensure the Order of Cell Cycle Events," Science 246:629-634.
Henderson et al., 1985, "Diagnosis of Ataxia-Telangiectasia by T-Lymphocyte Cloning Assay," Lancet 11:1242.
Hernandez et al., 1993, "A family showing no evidence of linkage between the ataxia telangiectasia gene and chromosome 11q22-23," J. Med. Genet. 30:135-140.
Huse et al., 1989, "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," Science 246:1275-1281.
Jaspers and Bootsma, 1982, "Abnormal levels of UV-induced unscheduled DNA synthesis in ataxia telangiectasia cells after exposure to ionizing radiation," Mutat. Res. 92:439-446.
Jaspers et al., 1988, "Genetic complementation analysis of ataxia telangiectasia and Nijmegen breakage syndrome: a survey of 50 patients," Cytogenet. Cell Genet. 49:259-263.
Jones et al., 1986, "Replacing the complementarity-determining regions in a human antibody with those from a mouse," Nature 321:522-525.
Kastan et al., 1992, "A Mammalian Cell Cycle Checkpoint Pathway Utilizing p53 and GADD45 Is Defective in Ataxia-Telangiectasia," Cell 71:587-597.
Kastan et al., 1991, "Participation of p53 Protein in the Cellular Response to DNA Damage," Cancer Res. 51:6304-6311.
Khanna & Lavin, 1993, "Ionizing radiation and UV induction of p53 protein by different pathways in ataxia-telangiectasia cells," Oncogene 8:3307-3312.
Kohler and Milstein, 1975, "Continuous cultures of fused cells secreting antibody of predefined specificity," Nature 256:495-497.
Kosbor and Roder, 1983, "The production of monoclonal antibodies from human lymphocytes," Immunology Today 4:72-79.
Kuerbitz et al., 1992, "Wild-type p53 is a cell cycle checkpoint determinant following irradiation," Proc. Natl. Acad. Sci. U.S.A. 89:7491-7495.
Kuhnlein and Paterson, 1990, "Increased uracil-DNA glycosylase, AP-DNA binding protein and deoxyribonuclease activities in tumor and SV40-transformed cell lines of human origin," Carcinogenesis 11:117-121.
Lehmann et al., 1979, "Abnormal Kinetics of DNA Synthesis in Ultraviolet Light-irradiated Cells from Patients with Cockayne's Syndrome," Cancer Res. 39:4237-4241.
Mirzayans and Paterson, 1991, "Lack of correlation between hypersensitivity to cell killing and impaired inhibition of DNA synthesis in ataxia telangiectasia fibroblasts treated with 4-nitroquinoline 1-oxide," Carcinogenesis 12:19-24.
Mohamed et al., 1987, "A Defect in DNA Topoisomerase II Activity in Ataxia-Telangiectasia Cells," Biochem. Biophys. Res. Commun. 149:233-238.
Morrison et al., 1984, "Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains," Proc. Natl. Acad. Sci. U.S.A. 81:6851-6855.
Mulligan, R.C., Chapter 8, In: Experimental Manipulation of Gene Expression, Academic Press, pp. 155-173 (1983).
Murnane and Painter, 1982, "Complementation of the defects in DNA synthesis in irradiated and unirradiated ataxia-telangiectasia cells," Proc. Natl. Acad. Sci. U.S.A. 79:1960-1963.
Neuberger et al., 1984, "Recombinant antibodies possessing novel effector functions," Nature 312:604-608.
Painter and Young, 1980, "Radiosensitivity in ataxia-telangiectasia: A new explanation," Proc. Natl. Acad. Sci. U.S.A. 77:7315-7317.
Pippard et al., 1988, "Cancer in Homozygotes and Heterozygotes of Ataxia-Telangiectasia and Xeroderma Pigmentosum in Britain," Cancer Res. 48:2929-2932.
Reichmann et al., 1988, "Reshaping human antibodies for therapy," Nature 332:323-327.
Rosin and Ochs, 1989, "Heterogeneity of chromosomal breakage levels in epithelial tissue of ataxia-telangiectasia homozygotes and heterozygotes," Hum. Genet. 83:133-138.
Rosin and Ochs, 1986, "In vivo chromosomal instability in ataxia-telangiectasia homozygotes and heterozygotes," Hum. Genet. 74:335-340.
Russo et al., 1989, "Molecular analysis of a t(14;14) translocation in leukemic T-cells of an ataxia telangiectasia patient," Proc. Natl. Acad. Sci. U.S.A 86:602-606.
Eng. J. Med. 300:700-704.
Shaham and Becker, 1981, "The Ataxia Telangiectasia Clastogenic Factor is a Low Molecular Weight Peptide," Hum. Genet. 58:422-424.
Shiloh et al., 1989, "G.sub.2 chromosomal radiosensitivity in families with ataxia-telangiectasia," Hum. Genet. 84:15-18.
Swift et al., 1991, "Incidence of Cancer in 161 Families Affected by Ataxia-Telangiectasia," New Eng. J. Med. 325:1831-1836.
Swift et al., 1987, "Breast and Other Cancers in Families with Ataxia-Telangiectasia," New Eng. J. Med. 316:1289-1294.
Takeda et al., 1985, "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences," Nature 314:452-454.
Verhoeyen et al., 1988, "Reshaping Human Antibodies: Grafting an Antilysozyme Activity," Science 239:1534-1536.
Woods and Taylor, 1992, "Ataxia Telangiectasia in the British Isles: The Clinical and Laboratory Features of 70 Affected Individuals," Quart. J. Med. 82:169-179.
Wooster et al., 1993, "Absence of linkage to the ataxia telangiectasia locus in familial breast cancer," Hum. Genet. 92:91-94.

Affiliated with

Also associated with

Rating

Human fibroblast diffusable factors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Human fibroblast diffusable factors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human fibroblast diffusable factors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1254428